280 related articles for article (PubMed ID: 33135115)
1. CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies.
Barat M; Guegan-Bart S; Cottereau AS; Guillo E; Hoeffel C; Barret M; Gaujoux S; Dohan A; Soyer P
Abdom Radiol (NY); 2021 May; 46(5):2219-2235. PubMed ID: 33135115
[TBL] [Abstract][Full Text] [Related]
2. Rational use of
Bisschop C; de Heer EC; Brouwers AH; Hospers GAP; Jalving M
Crit Rev Oncol Hematol; 2020 Sep; 153():103044. PubMed ID: 32673997
[No Abstract] [Full Text] [Related]
3. Whole-Body [
Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
[TBL] [Abstract][Full Text] [Related]
4. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study.
Orcurto V; Denys A; Voelter V; Schalenbourg A; Schnyder P; Zografos L; Leyvraz S; Delaloye AB; Prior JO
Melanoma Res; 2012 Feb; 22(1):63-9. PubMed ID: 22027909
[TBL] [Abstract][Full Text] [Related]
5. [The role of preoperative (18)F-FDG PET-CT in lymphatic metastasis diagnosis of cutaneous malignant melanoma on extremities and trunk].
Zhang XX; Fang Y; Xu LB; Xu SF; Zhao ZG; Sun C; Ma PQ; Liu T; Yu SJ; Zhang WJ
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):372-378. PubMed ID: 29860765
[No Abstract] [Full Text] [Related]
6. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
7. Malignant Cutaneous Melanoma: Updates in PET Imaging.
Laudicella R; Baratto L; Minutoli F; Baldari S; Iagaru A
Curr Radiopharm; 2020; 13(1):14-23. PubMed ID: 31749439
[TBL] [Abstract][Full Text] [Related]
8. The role of FDG-PET-CT is limited in initial staging of nodal metastasis for thin cutaneous melanoma.
Cheng D; McNicoll CF; Kirgan D; Jones MS; Rivera MR; Doyle GM; De Guzman MD; Baynosa J; St Hill CR
Am J Surg; 2021 Apr; 221(4):737-740. PubMed ID: 32354604
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
12. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Melanoma and Skin Malignancies.
Lee ST; Kovaleva N; Senko C; Kee D; Scott AM
PET Clin; 2024 Apr; 19(2):231-248. PubMed ID: 38233284
[TBL] [Abstract][Full Text] [Related]
13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
14. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Abbott RA; Acland KM; Harries M; O'Doherty M
Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
[TBL] [Abstract][Full Text] [Related]
16. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Castello A; Lopci E
Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
[TBL] [Abstract][Full Text] [Related]
17. [Role of FDG PET-CT in cutaneous melanoma].
Nicol I; Chuto G; Gaudy-Marqueste C; Brenot-Rossi I; Grob JJ; Richard MA
Bull Cancer; 2008 Nov; 95(11):1089-101. PubMed ID: 19036682
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of positron emission tomography for the detection of melanoma metastases.
Holder WD; White RL; Zuger JH; Easton EJ; Greene FL
Ann Surg; 1998 May; 227(5):764-9; discussion 769-71. PubMed ID: 9605668
[TBL] [Abstract][Full Text] [Related]
19. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
20.
Hicks RJ; Iravani A; Sandhu S
PET Clin; 2020 Jan; 15(1):11-22. PubMed ID: 31735298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
